Bharat Biotech seeks DCGI’s approval for trials of nasal vaccine for COVID-19

Bharat Biotech has sent a proposal to the Drugs Controller General of India to conduct phase 1 trials of a nasal vaccine for COVID-19. As per the official, the application has been sent to the drug regulatory body and the matter is yet to be taken up.

In recent, COVID-19 vaccines of Bharat Biotech’s ‘COVAXIN’ and Serum Institute’s ‘Covishield’ were granted permission by DGCI for the restricted use in an emergency situation on January 3, 2021.

This came a day after Bharat Biotech had announced the successful completion of volunteer enrolment for COVAXIN’s phase 3 clinical trials. The Union Health Minister, Dr. Harsh Vardhan had also informed that both the vaccines for COVID-19 are on the verge of being available in India.

Leave a Reply